Antibody Drugs: Technologies and Global Markets
The global market for antibody drugs was worth nearly $63.4 billion in 2013. This market is expected to grow at a compound annual growth rate (CAGR) of 12.2% between 2014 and 2019 resulting in totals nearly $68.9 billion in 2014 and $122.6 billion globally in 2019.
- An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
- Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
- Analysis and assessment of the therapeutic applications of mAbs in human medicine.
- A look at the antibody industry as a whole as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
- Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.
The scope of this report embraces the key market analysis, market drivers, market constraints, and also competitive developments and trends in this market. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections and market shares.
The study involves the antibody drugs used in the pharmaceutical and the biopharmaceutical markets. This report analyzes and assesses therapeutic applications of mAbs in human medicine, including the combination of mAbs when they are attached to cytotoxic agent such as with antibody-drug conjugates (ADCs).
Excluded from this report is information regarding polyclonal antibodies, as well as screening equipment and diagnostic uses (such as for imaging purposes) of mAbs. Also excluded is discussion relating to the research applications of mAbs and therapeutic antibodies for veterinary use.
Complete geographical analysis of market is also studied in report. The emerging market for mAbs includes countries such as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia, New Zealand and so forth. Profiles of key market players are also covered for this report. The U.S. and Europe markets are also covered.
The technological issues include all the latest trends, for example, the human antimouse antibody (HAMA) problem because of murine antibodies and its resolution by using chimeric, human and humanized antibodies instead of murine antibodies for therapy, pipeline products and developments. Also included in the report are comprehensive profiles of companies that lead the biotechnology and pharmaceutical industry in the research and development (R&D) of antibody drugs.
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011. With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.
- The global market for monoclonal therapeutic and diagnostic antibodies increased from $26 billion in 2006 to an estimated $31 billion by the end of 2007. It should reach $56 billion by 2012, a compound annual growth rate (CAGR) of 13%.
- In 2007, the U.S. Food and Drug Administration approved 21 therapeutic monoclonal antibodies for therapeutic use under a drug approval review.
- Monoclonal antibodies are a significant part of effective medical treatment and of financial deals within the biotechnology and pharmaceutical sectors of the economy.
The worldwide market for therapeutic and diagnostic antibodies is estimated at $15 billion in 2005 and will rise at an average annual growth rate (AAGR) of 11.5% to nearly 26 billion in 2010.
Therapeutic antibodies dominate the market and are projected to have an AAGR of 11.4%, reaching $25.7 billion in 2010.
The therapeutic monoclonal antibody segment will rise at an AAGR of 12.4% while the therapeutic polyclonal market, driven more by volume and demand than innovation, is projected to see an AAGR of only 4%.
The diagnostic imaging market, though small, will experience an average annual growth near 17%, reaching $147 million in 2010.
As of May 2002, there were 11 therapeutic monoclonal antibody products on the U.S. market. Worldwide, there were an estimated 470 monoclonal antibody products in development by more than 200 companies for the treatment of virtually every debilitating disease. Approximately 70 of these monoclonal antibody products were in clinical trials. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), monoclonal antibody products represented approximately 20% of all products in development and 33% of all biotech products in development by its members.
The therapeutic monoclonal antibody market is projected to have an average annual growth rate (AAGR) of approximately 25% throughout the forecast period. The therapeutic polyclonal antibody market, which is driven more by volume and demand than innovation, is projected to see an AAGR of just less than 11%. The diagnostic imaging market, though small, will see average annual growth exceeding 28% throughout the forecast period.
Antibody-based drugs, in particular monoclonal antibody-based products, are on the brink of significant commercial growth. New developments are spurred in part by advances in technology that have now surmounted previous technical barriers to commercialization.
The information and analyses presented in this report on antibody-based drugs is an important asset in decision-making for managers involved in development, marketing, market research, product development, mergers and acquisitions, licensing, management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry.
The study provides a comprehensive analysis of the current markets for antibody drugs and, in particular, the market potential of promising drugs and technologies under development.